dc.date.accessioned | 2022-04-26T16:04:26Z | |
dc.date.available | 2022-04-26T16:04:26Z | |
dc.date.created | 2022-01-26T11:44:14Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Rønning, Marit Hjellvik, Vidar Sakshaug, Solveig Blix, Hege Salvesen Midtvedt, Karsten Reisæter, Anna Varberg Holdaas, Hallvard Åsberg, Anders . Use of Statins in Kidney Transplant Recipients in Norway. International Journal of Environmental Research and Public Health (IJERPH). 2022, 19(3), 1-10 | |
dc.identifier.uri | http://hdl.handle.net/10852/93791 | |
dc.description.abstract | Kidney transplant recipients (KTRs) experience increased risk of cardiovascular disease. Guidelines recommend HMG-CoA reductase inhibitor (statin) therapy when tolerated. We aimed to study changes in the prescription of statins and patients’ adherence to treatment over time. A population-based observational study utilizing linked data from the Norwegian Renal Registry (national coverage of 99.9%) and the Norwegian Prescription Database was performed. Data from a total of 2250 first KTRs were included (mean age—54 years, 69% men). Dispensed prescriptions of statins and immunosuppressants for the period 2004–2016 for all first KTRs engrafted in the period 2005–2015 were analyzed. Seventy-two percent received statins the first year after kidney transplantation and the proportion increased with age. The proportion receiving a statin varied according to the time frame of transplantation (77% in 2005–2010 vs. 66% in 2012–2015). Among new users of statins, 82% of the patients were adherent both the second and third year after kidney transplantation, while the corresponding figure for those already receiving statins before transplantation was 97%. Statin continuation rates in KTRs were high. In conclusion, our findings show a slightly lower overall proportion of patients receiving statins after kidney transplants than the national target level of 80%. The proportion of statin users increased with the age of the KTRs but showed a decreasing trend as time progressed. | |
dc.language | EN | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.title | Use of Statins in Kidney Transplant Recipients in Norway | |
dc.title.alternative | ENEngelskEnglishUse of Statins in Kidney Transplant Recipients in Norway | |
dc.type | Journal article | |
dc.creator.author | Rønning, Marit | |
dc.creator.author | Hjellvik, Vidar | |
dc.creator.author | Sakshaug, Solveig | |
dc.creator.author | Blix, Hege Salvesen | |
dc.creator.author | Midtvedt, Karsten | |
dc.creator.author | Reisæter, Anna Varberg | |
dc.creator.author | Holdaas, Hallvard | |
dc.creator.author | Åsberg, Anders | |
cristin.unitcode | 185,15,23,0 | |
cristin.unitname | Farmasøytisk institutt | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.cristin | 1990303 | |
dc.identifier.bibliographiccitation | info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=International Journal of Environmental Research and Public Health (IJERPH)&rft.volume=19&rft.spage=1&rft.date=2022 | |
dc.identifier.jtitle | International Journal of Environmental Research and Public Health (IJERPH) | |
dc.identifier.volume | 19 | |
dc.identifier.issue | 3 | |
dc.identifier.doi | https://doi.org/10.3390/ijerph19031370 | |
dc.identifier.urn | URN:NBN:no-96345 | |
dc.type.document | Tidsskriftartikkel | |
dc.type.peerreviewed | Peer reviewed | |
dc.source.issn | 1661-7827 | |
dc.identifier.fulltext | Fulltext https://www.duo.uio.no/bitstream/handle/10852/93791/1/Ronning_2022_Use.pdf | |
dc.type.version | PublishedVersion | |
cristin.articleid | 1370 | |